In HER2 Breast Cancer Herceptin And Chemo Improves Response Rates Without Major Adverse Effects
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.
ACORN Presents Findings Of Collaborative Metastatic Colorectal Cancer Research
On Tuesday, April 15th, Lee S. Schwartzberg, MD, FACP, President of the Accelerated Community Oncology Research Network, Inc. presented findings at the American Association for Cancer Research annual meeting in San Diego. The Phase II study tested a novel biologic agent in conjunction with chemotherapy used in colorectal cancer with encouraging interim results.
Genetic Immunity Announces Data Related To The DermaVir Nanomedicine Patch In The Journal Of Immunology
Genetic Immunity(R), a US/Hungarian clinical-stage company focused on patented nanomedicines for immune amplification, announced that the Journal of Immunology published findings on a key biomarker currently being used in clinical studies of its lead HIV/AIDS nanomedicine candidate, the DermaVir Patch.
InterMune Announces Progress On Pirfenidone In IPF
InterMune, Inc. (Nasdaq: ITMN) announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The roll-over study will be open to patients who complete one of the two concurrent Phase 3 CAPACITY studies of pirfenidone in IPF.
Trubion Announces Initiation Of Phase 1 Study Of SBI-087 For The Treatment Of Rheumatoid Arthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA).
Inaccuracies In Studies Of Cancer Treatment Revealed
Certain biases may exist in observational studies that compare outcomes of different cancer therapies, making the results questionable. That is the conclusion of a new study published in the June 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
What People Should Know When Enrolling In Clinical Trials
An article published in the March 2008 issue of the Journal of Medical Ethics explores often-neglected aspects of the "therapeutic misconception, " an ethical problem present in many clinical research studies. This misunderstanding arises when research subjects believe they will be receiving optimal medical care as opposed to being participants in an experimental trial whose main goal is the benefit of future patients.
Sirtris Announces SRT501 Lowers Glucose In Twice-Daily Dosing Clinical Trial
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced positive top-line data from its twice-daily dosing study of SRT501, the company's proprietary formulation of resveratrol.
New Data Confirm Pramipexole Mirapexin R Sifrol R Can Significantly Reduce Sleep Disturbance For People With Restless Legs Syndrome RLS
A new study has shown that pramipexole (Mirapexin /Sifrol ) can significantly reduce sleep disturbance, often the most troublesome symptom experienced by people with Restless Legs Syndrome (RLS).1 The important finding, presented today at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, U.
Comparison Of Latest Rheumatoid Arthritis Drugs
Findings published in the open access journal BMC Musculoskeletal Disorders shows that the latest class of drugs used to treat rheumatoid arthritis (RA) are better than standard anti-inflammatories.RA is a chronic, debilitating, inflammatory disease of the joints, which is usually treated with anti-inflammatory drugs such as methotrexate or steroids.